PRELIMINARY PROGRAM

THE FUTURE OF ADVANCED THERAPEUTICS IN NEUROLOGY

Monday, October 19, 2026

9:00-9:15 | WELCOME AND OPENING REMARKS

  • Guy Rouleau, MD, Director, The Neuro (Montreal Neurological Institute-Hospital)
  • Dominique Bérubé, PhD, Vice-President, Research + Innovation, McGill University

9:15-10:30 | SESSION 1: KEYNOTE PRESENTATION

  • First in Human Trial with Personalized CRISPR Gene Editing Therapy
  • 40 Years of Innovation in Clinical Research at The Neuro
    Massimo Pandolfo, MD; Medical Director, Clinical Research Unit at The Neuro

10:30-11:00 | COFFEE BREAK

11:00-12:15 | SESSION 2: GENE AND GENE-EDITING THERAPIES

  • Base Editing in Rare Neurological Disorders
  • Prime Editing as a Versatile Tool for Gene Therapy
  • Gene Therapy Efforts at The Neuro

12:15-1:45 | LUNCH + POSTER SESSION

1:45-3:00 | SESSION 3: THE PROMISE AND CHALLENGES OF CELL THERAPY

  • CAR-T for Brain Tumours
  • Cell Therapy for Parkinson’s Disease
  • Cell Therapy for Spinal Cord Injuries

3:00-3:15 | COFFEE BREAK

3:15-4:30 | SESSION 4: NOTES FROM A DECADE OF RNA THERAPEUTICS

  • The Success of RNA in Treating Spinal Muscular Atrophy
  • Advanced Delivery Methods for RNA Therapies
  • ASOs for Neurodegenerative or adult rare disease

4:30-6:00 | NETWORKING COCKTAIL

Powered by
►
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
►
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
►
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
►
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
Powered by